Click below to schedule a Consultation with one of our Mold Professionals
NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage
Curcumin nanoemulsion suppresses HPV oncogenes and inhibits cervical cancer progression: in vitro and in vivo study
Glutathione 1,500mg Summary Description: Glutathione is a master antioxidant peptide essential for protecting cells from oxidative damage, detoxifying harmful substances, and supporting a robust immune system
GHK-Cu works by supporting your bodys natural regenerative processes
